Medical Cannabis

The Shift

On April 28, 2026, the Drug Enforcement Administration reclassified state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act — the most significant federal cannabis policy change since the CSA was enacted in 1970.

For over half a century, the federal government maintained that marijuana had "no currently accepted medical use in treatment." That changed with AG Order 6754-2026. State-licensed medical marijuana now sits in Schedule III — the same category as ketamine, anabolic steroids, and Tylenol with codeine — with explicit federal recognition of its medical value.

We've known this for a long time. Now the law agrees.

What Schedule III Means

For patients.
Medical marijuana patients are no longer using a substance the federal government classifies as having zero medical value. State medical marijuana programs now operate with explicit federal recognition. Practitioners face reduced risk when recommending cannabis-based treatments. And the door is open for insurance coverage, clinical guidelines, and the kind of evidence-based medicine that patients deserve.

For research.
The DEA's final rule protects researchers who obtain marijuana from state-licensed operators — no civil or criminal liability under the Controlled Substances Act. For the first time, clinical trials can source cannabis from the regulated commercial market rather than solely from government-grown supply. That means real research on real products — including cannabis beverages — using the same formulations patients actually consume.

How We Make Medical Cannabis Beverages

Cannabis isn't water-soluble — you can't just stir it into a drink. We use nano-emulsion technology to break cannabinoid oil into particles small enough to suspend uniformly in liquid, creating beverages with faster onset, more consistent absorption, and precise dosing in every serving.

Extraction. All cannabis inputs undergo supercritical CO2 extraction — the industry standard for producing clean, full-spectrum cannabis oil without residual solvents.

Emulsification. The extracted oil is processed through nano-emulsion to create water-compatible cannabinoid particles, enabling even distribution throughout the beverage.

Formulation. Each recipe is precision-dosed and crafted with all-natural ingredients — no artificial flavors, sweeteners, or preservatives. We locally source our ingredients whenever possible.

Testing. Every batch is tested by independent, accredited laboratories at three stages: raw material, extracted oil, and finished product. We test for potency, pesticides, heavy metals, microbials, and residual solvents — because medical-grade means knowing exactly what's in the bottle.

The Federal Rescheduling: Key Details

The DEA's final rule (AG Order 6754-2026) rescheduled two categories of marijuana from Schedule I to Schedule III:

1. FDA-approved drug products containing marijuana
2. Marijuana subject to a state medical marijuana license — any form, including flower, extract, and infused products

The rule creates an expedited DEA registration pathway for state-licensed medical marijuana operators. Applicants submit proof of a valid state license, and the DEA must register the applicant unless doing so would be inconsistent with the public interest. State licensees who apply within 60 days of publication may continue operating under their state license during the pendency of the application.

Recreational marijuana remains Schedule I under federal law. The rescheduling applies exclusively to marijuana subject to state medical marijuana licenses and FDA-approved products.

Talk to Your Doctor

Cannabis medicine is real medicine — and the federal government now agrees. If you're considering cannabis as part of a treatment plan, talk to a qualified healthcare provider. Washington patients can apply for a medical marijuana recognition card through the Department of Health, which provides access to medical-endorsed retailers, tax exemption, and enhanced possession limits.